Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 5/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 5/20 | 0.37 |
| ▸ | TYMP | P19971 | 3/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | CCR10 | P46092 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5311355 | 1.00 | KMT2A (0.45) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL5310582 | 1.00 | KMT2A (0.45) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL5313313 | 0.92 | KMT2A (0.41) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL5316299 | 0.92 | KMT2A (0.41) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL5314246 | 0.90 | KMT2A (0.39) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL13647157 | 0.90 | KMT2A (0.43) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL5311307 | 0.89 | KMT2A (0.43) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL8597227 | 0.88 | KMT2A (0.42) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL8597217 | 0.88 | KMT2A (0.42) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL5312576 | 0.88 | KMT2A (0.42) | KMT2ALMNATHRBCYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0629617-B2 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INT BV (NL) | 2007-09-26 | — | — | EP | claimed |
| EP-1377557-A1 | METHODS OF SYNTHESIZING HETEROATOM-BEARING LIGANDS AND INTERMEDIATE USED THEREFOR | BRACCO INTERNATIONAL B.V. (NL) | 2004-01-07 | — | — | EP | claimed |
| WO-2002076952-A1 | METHODS OF SYNTHESIZING HETEROATOM-BEARING LIGANDS AND INTERMEDIATE USED THEREFOR | BRACCO INTERNATIONAL B.V. (US) | 2002-10-03 | — | — | WO | claimed |
| US-6384232-B1 | RADIOLOGY, HYPOXIC TISSUE CYTOTOXINS, RADIOSENSITIZERS; REACT N-(2,3-EPOXYPROPYL)PHTHALIMIDE WITH 2-NITRO-IMIDAZOLE; 6-((2-NITRO-1H-IMIDAZOL-1-YL)METHYL)-5-OXA-4,8-DIAZA UNDECANE-2,10-DIONE DIOXIME COMPOUNDS | BRACCO INTERNATIONAL B.V. (NL) | 2002-05-07 | — | — | US | claimed |
| CN-1055685-C | Heteroatom-bearing ligands and metal complexes thereof | BRAKER INTERNAT B V (NL) | 2000-08-23 | — | — | CN | claimed |
| EP-0629617-B1 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INT BV (NL) | 1998-04-29 | — | — | EP | claimed |
| US-5665329-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-09-09 | — | — | US | claimed |
| US-5627286-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-05-06 | — | — | US | claimed |
| CN-1099388-A | Heteroatom-bearing ligands and metal complexes thereof | BRISTOL MYERS SQIBB COMPANY (US) | 1995-03-01 | — | — | CN | claimed |
| EP-0629617-A1 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO International B.V. (NL) | 1994-12-21 | — | — | EP | claimed |
| EP-1404376-B1 | RADIOPHARMACEUTICAL FORMULATIONS | BRACCO IMAGING SPA (IT) | 2009-10-14 | — | — | EP | disclosed |
| EP-0629617-B2 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INT BV (NL) | 2007-09-26 | — | — | EP | disclosed |
| EP-1377557-B1 | METHODS OF SYNTHESIZING HETEROATOM-BEARING LIGANDS AND INTERMEDIATE USED THEREFOR | BRACCO INT BV (NL) | 2006-04-05 | — | — | EP | disclosed |
| US-6933391-B2 | Methods of synthesizing heteroatom-bearing ligands and intermediate used therefor | BRACCO INTERNATIONAL B.V. (NL) | 2005-08-23 | — | — | US | disclosed |
| US-20050074402-A1 | Radiopharmaceutical formulations | BRACCO IMAGING S.P.A. (IT) | 2005-04-07 | — | — | US | disclosed |
| US-5656254-A | Polyaza heteroatom-bearing ligands and metal complexes thereof for imaging or radiotherapy | BRACCO INTERNATIONAL B.V. | 1997-08-12 | — | — | US | disclosed |
| US-5627286-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-05-06 | — | — | US | disclosed |
| US-5608110-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-03-04 | — | — | US | disclosed |
| CN-1099388-A | Heteroatom-bearing ligands and metal complexes thereof | BRISTOL MYERS SQIBB COMPANY (US) | 1995-03-01 | — | — | CN | disclosed |
| EP-0629617-A1 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO International B.V. (NL) | 1994-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050074402-A1 | Radiopharmaceutical formulations | SDHB, GPX4, SDHA | KMT2A 4656/4885LMNA 2780/4885THRB 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.